The U.S. Food and Drug Administration recently approved Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) for ...

Understand the differences between hereditary and histamine-mediated angioedema, including their symptoms, causes, and ...

A year ago, Pfizer tied a subcutaneous injection of the highest dose of the anti-GDF-15 antibody ponsegromab once every four ...

Earlier this month, BioArctic AB announced that Leqembi Iqlik, the subcutaneous autoinjector formulation of lecanemab, became available in the U.S. as a maintenance dosing option for early Alzheimer's ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today ...

Halozyme Therapeutics has been busy. While fighting a patent dispute with Merck & Co. | Halozyme scoured very broadly for ...

GSK’s ViiV Healthcare and its bimonthly pre-exposure prophylaxis (PrEP) medicine Apretude had to make room for another ...

Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on ...

1. About lecanemab (generic name, brand name: LEQEMBI®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal ...

Kiniksa Pharmaceuticals International said the Food and Drug Administration has granted orphan drug designation to KPL-387 for the treatment of pericarditis, which includes recurrent pericarditis.

Bimeda US recently announced the launch of Gamrozyne ™, the first and only bioequivalent to Zactran ® (Boehringer-Ingelheim ® ...